Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Feb 7

PMID 32023959

Citations 4

Authors

Natasha Adlakha

Mark W Russo

Affiliations

Soon will be listed here.

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) is effective at treating ascites and variceal bleeding but may be associated with increased morbidity and mortality in older patients. Our aim was to report outcomes in patients 70 years and older who underwent TIPS because data are limited in this population. We performed a retrospective review of patients who underwent TIPS at our institution over 10 years. We matched those 70 years and older to those 50-59 years old by year of TIPS and the Model for End-Stage Liver Diseae-Sodium (MELD-Na). Thirty-day readmissions were higher in the elderly group ( = 50) compared to the younger group ( = 50), = 17 (34%) and = 6 (12%) ( = 0.02), respectively. Readmissions for post-TIPS hepatic encephalopathy (HE) in the older and younger groups were = 14 (28%) and = 5 (10%) ( = 0.04), respectively. Thirty-day mortality was higher in the older group compared to the younger group, but the difference was not statistically significant, 24% and 12%, respectively ( = 0.19). TIPS can be performed safely in patients 70 years and older, but the overall readmissions, and specifically for HE, were significantly higher in older patients. Patients 70 years and older should be followed closely after TIPS, and early introduction of treatment for encephalopathy should be considered.

Citing Articles

Utility of Advanced Age as a Predictor of Outcomes in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt.

Waidyaratne G, Jalil S, Liu A, Liyanarachchi S, Makary M, Rikabi A Dig Dis Sci. 2025; .

PMID: 40024959 DOI: 10.1007/s10620-025-08940-0.

Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy-A Review of the Past Decade's Literature Focusing on Incidence, Risk Factors, and Prophylaxis.

Friis K, Thomsen K, Laleman W, Montagnese S, Vilstrup H, Lauridsen M J Clin Med. 2024; 13(1).

PMID: 38202028 PMC: 10779844. DOI: 10.3390/jcm13010014.

Chronic Liver Disease in the Older Patient-Evaluation and Management.

DiLeo D, Gidener T, Aytaman A Curr Gastroenterol Rep. 2023; 25(12):390-400.

PMID: 37991713 DOI: 10.1007/s11894-023-00908-2.

Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis.

Ahmed Z, Farooq U, Arif S, Aziz M, Iqbal U, Nawaz A Gastroenterology Res. 2023; 15(6):325-333.

PMID: 36660467 PMC: 9822662. DOI: 10.14740/gr1571.

Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.

Rajesh S, George T, Philips C, Ahamed R, Kumbar S, Mohan N World J Gastroenterol. 2020; 26(37):5561-5596.

PMID: 33088154 PMC: 7545393. DOI: 10.3748/wjg.v26.i37.5561.

References

Gaba R, Omene B, Podczerwinski E, Knuttinen M, Cotler S, Kallwitz E . TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol. 2011; 23(2):227-35. DOI: 10.1016/j.jvir.2011.10.015. View

Riggio O, Angeloni S, Salvatori F, De Santis A, Cerini F, Farcomeni A . Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008; 103(11):2738-46. DOI: 10.1111/j.1572-0241.2008.02102.x. View

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

Peter P, Andrej Z, Katarina S, Manca G, Pavel S . Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with recurrent variceal hemorrhage. Gastroenterol Res Pract. 2013; 2013:398172. PMC: 3625580. DOI: 10.1155/2013/398172. View

Ferral H, Patel N . Selection criteria for patients undergoing transjugular intrahepatic portosystemic shunt procedures: current status. J Vasc Interv Radiol. 2005; 16(4):449-55. DOI: 10.1097/01.RVI.0000149508.64029.02. View

Russo M, Sood A, Jacobson I, Brown Jr R . Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol. 2003; 98(11):2521-7. DOI: 10.1111/j.1572-0241.2003.08664.x. View

Laberge J, Somberg K, Lake J, Gordon R, Kerlan Jr R, Ascher N . Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology. 1995; 108(4):1143-51. DOI: 10.1016/0016-5085(95)90213-9. View

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

Saad N, Rude M, Darcy M, Hanin J, Wentworth A, Korenblat K . Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt. Ann Hepatol. 2019; 15(2):215-221. DOI: 10.5604/16652681.1193716. View

10.

Casadaban L, Parvinian A, Minocha J, Lakhoo J, Grant C, Ray Jr C . Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes. Dig Dis Sci. 2014; 60(4):1059-66. DOI: 10.1007/s10620-014-3391-0. View

11.

Deschenes M, Dufresne M, Bui B, Fenyves D, Spahr L, Roy L . Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol. 1999; 94(5):1361-5. DOI: 10.1111/j.1572-0241.1999.01112.x. View

12.

Pan J, Chen C, Caridi J, Geller B, Firpi R, Machicao V . Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years' experience from a single tertiary medical center. J Vasc Interv Radiol. 2008; 19(11):1576-81. DOI: 10.1016/j.jvir.2008.07.021. View

13.

Thuluvath P, Bal J, Mitchell S, Lund G, Venbrux A . TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci. 2003; 48(3):542-50. DOI: 10.1023/a:1022544917898. View

14.

Runyon B . Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087-107. DOI: 10.1002/hep.22853. View

15.

Syed M, Karsan H, Ferral H, Shaikh A, Waheed U, Akhter T . Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension. World J Hepatol. 2012; 4(2):35-42. PMC: 3295850. DOI: 10.4254/wjh.v4.i2.35. View

16.

Kim W, Lake J, Smith J, Schladt D, Skeans M, Noreen S . OPTN/SRTR 2017 Annual Data Report: Liver. Am J Transplant. 2019; 19 Suppl 2:184-283. DOI: 10.1111/ajt.15276. View

17.

Li Y, Wang F, Chen X, Li B, Meng W, Qin C . Short outcome comparison of elderly patients versus nonelderly patients treated with transjugular intrahepatic portosystemic stent shunt: A propensity score matched cohort study. Medicine (Baltimore). 2017; 96(29):e7551. PMC: 5521917. DOI: 10.1097/MD.0000000000007551. View

18.

Gaba R, Bui J, Cotler S, Kallwitz E, Mengin O, Martinez B . Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization. Hepatol Int. 2011; 4(4):749-56. PMC: 2994622. DOI: 10.1007/s12072-010-9206-2. View

19.

Lee E, Kuei A, Saab S, Busuttil R, Durazo F, Han S . Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World J Gastroenterol. 2016; 22(25):5780-9. PMC: 4932213. DOI: 10.3748/wjg.v22.i25.5780. View

20.

Somberg K, Riegler J, Laberge J, Bachetti P, Roberts J, Lake J . Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol. 1995; 90(4):549-55. View